Cytokinetics: Biopharma Specialist for Heart Muscle Therapies Drives Myqorzo Expansion!
Reading Time: 3 minutes
With a strong US market launch of Myqorzo, Cytokinetics is transforming into a commercial biotech company. The successful US market launch of Myqorzo and the planned introduction in Germany support the peak revenue potential of $3.3 billion by 2038. The Phase 3 data from the ACACIA-HCM study supported the FDA's expansion of approval for non-obstructive HCM (nHCM). According to Citi analysts, this opportunity is underestimated. Cytokinetics (CYTK) is a biopharmaceutical company focused on the discovery and development of muscle...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
